Maintenance of antifracture efficacy over 10 years with strontium ranelate in postmenopausal osteoporosis

J. Y. Reginster, J. M. Kaufman, S. Goemaere, J. P. Devogelaer, C. L. Benhamou, D. Felsenberg, M. Diaz-Curiel, M. L. Brandi, J. Badurski, J. Wark, A. Balogh, O. Bruyère, C. Roux

Research output: Contribution to journalArticle

80 Citations (Scopus)

Abstract

In an open-label extension study, BMD increased continuously with strontium ranelate over 10 years in osteoporotic women (P < 0.01). Vertebral and nonvertebral fracture incidence was lower between 5 and 10 years than in a matched placebo group over 5 years (P < 0.05). Strontium ranelate's antifracture efficacy appears to be maintained long term. Introduction: Strontium ranelate has proven efficacy against vertebral and nonvertebral fractures, including hip, over 5 years in postmenopausal osteoporosis. We explored long-term efficacy and safety of strontium ranelate over 10 years. Methods: Postmenopausal osteoporotic women participating in the double-blind, placebo-controlled phase 3 studies SOTI and TROPOS to 5 years were invited to enter a 5-year open-label extension, during which they received strontium ranelate 2 g/day (n = 237, 10-year population). Bone mineral density (BMD) and fracture incidence were recorded, and FRAX® scores were calculated. The effect of strontium ranelate on fracture incidence was evaluated by comparison with a FRAX®-matched placebo group identified in the TROPOS placebo arm. Results: The patients in the 10-year population had baseline characteristics comparable to those of the total SOTI/TROPOS population. Over 10 years, lumbar BMD increased continuously and significantly (P < 0.01 versus previous year) with 34.5 ± 20.2% relative change from baseline to 10 years. The incidence of vertebral and nonvertebral fracture with strontium ranelate in the 10-year population in years 6 to 10 was comparable to the incidence between years 0 and 5, but was significantly lower than the incidence observed in the FRAX®-matched placebo group over 5 years (P < 0.05); relative risk reductions for vertebral and nonvertebral fractures were 35% and 38%, respectively. Strontium ranelate was safe and well tolerated over 10 years. Conclusions: Long-term treatment with strontium ranelate is associated with sustained increases in BMD over 10 years, with a good safety profile. Our results also support the maintenance of antifracture efficacy over 10 years with strontium ranelate.

Original languageEnglish
Pages (from-to)1115-1122
Number of pages8
JournalOsteoporosis International
Volume23
Issue number3
DOIs
Publication statusPublished - Mar 1 2012

Keywords

  • BMD
  • Long-term treatment
  • Osteoporotic fracture
  • Strontium ranelate

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Fingerprint Dive into the research topics of 'Maintenance of antifracture efficacy over 10 years with strontium ranelate in postmenopausal osteoporosis'. Together they form a unique fingerprint.

  • Cite this

    Reginster, J. Y., Kaufman, J. M., Goemaere, S., Devogelaer, J. P., Benhamou, C. L., Felsenberg, D., Diaz-Curiel, M., Brandi, M. L., Badurski, J., Wark, J., Balogh, A., Bruyère, O., & Roux, C. (2012). Maintenance of antifracture efficacy over 10 years with strontium ranelate in postmenopausal osteoporosis. Osteoporosis International, 23(3), 1115-1122. https://doi.org/10.1007/s00198-011-1847-z